Compounded Tirzepatide Cost: Full Price Breakdown in 2026

Compounded tirzepatide costs a fraction of what Eli Lilly charges for Mounjaro or Zepbound. That price gap is the reason telehealth platforms offering compounded versions have grown so quickly. But the sticker price on the homepage is not always the full story. Dose escalation, shipping fees, and consultation charges can change the math. We pulled pricing from two providers and compared them against brand-name costs to show what you will actually pay over 3, 6, and 12 months.

Compounded Tirzepatide Pricing by Provider

The table below shows current monthly costs from the two compounded tirzepatide providers we track. All prices are from provider websites as of October 2026.

BiltRx is the cheapest option at $129 per month for compounded tirzepatide. Arc-1 starts at $199.99 for the 2.5 mg dose but climbs to $399.99 at 7.5 mg. Both are dramatically cheaper than brand-name pricing at $1,499 per month. The gap between compounded and brand-name is where the savings conversation starts and where the tradeoffs begin.

Annual Cost Comparison

Monthly prices look manageable. Annual totals make the differences between providers and between compounded and brand-name products much more visible.

A patient on BiltRx compounded tirzepatide for a full year pays $1,548. The same patient on brand-name Mounjaro or Zepbound through BiltRx pays $17,988. That is a difference of $16,440 per year. Even the most expensive Arc-1 option at 7.5 mg ($4,799.88 annually) costs roughly 73% less than brand-name pricing. These numbers assume no insurance coverage, no manufacturer coupons, and no dose changes mid-year.

Why Compounded Is Cheaper

The price difference between compounded and brand-name tirzepatide is not a mystery. It comes down to two factors: who makes the drug and what regulatory pathway governs its production.

No Eli Lilly Markup

Eli Lilly spent billions developing tirzepatide, running the SURMOUNT and SURPASS clinical trial programs, and navigating FDA approval for both Mounjaro (type 2 diabetes) and Zepbound (chronic weight management). The $1,499 monthly price reflects that investment plus marketing costs, distribution margins, and profit targets. Compounding pharmacies do not bear those costs. They purchase tirzepatide as a bulk active pharmaceutical ingredient and compound it into injectable formulations based on individual prescriptions. There is no national advertising budget, no sales force calling on physicians, and no shareholder expectation built into the price.

503A Pharmacy Economics

A 503A compounding pharmacy operates under Section 503A of the Federal Food, Drug, and Cosmetic Act. These pharmacies compound medications in response to individual patient prescriptions. They do not need to run clinical trials or submit a New Drug Application. Their overhead is lower than a large-scale pharmaceutical manufacturer, and they pass some of that savings on to the patient. The tradeoff is that compounded products are not FDA-approved. They do not undergo the same level of regulatory review as brand-name drugs. The FDA does not verify the potency, purity, or sterility of compounded formulations the way it does for commercially manufactured products. State boards of pharmacy regulate 503A pharmacies, and standards can vary.

Hidden Costs to Watch

The advertised monthly price is not always the price you pay. Several additional costs can appear depending on which provider you choose and how your treatment progresses.

Consultation Fees

BiltRx includes the consultation in the monthly subscription. Arc-1 advertises a free consultation. Neither provider charges a separate consultation fee at signup based on current website information. However, some telehealth platforms in this space charge $50 to $150 for the initial medical evaluation and additional fees for follow-up visits. Confirm whether your provider's consultation is truly free or whether it is bundled into the medication cost.

Shipping Charges

Arc-1 includes free shipping on all orders. BiltRx does not specify a flat shipping rate on its website. Cold-chain shipping for injectable medications requires insulated packaging and ice packs, which can add $10 to $30 per shipment at providers that charge separately. Over 12 months, shipping adds up. If your provider charges $20 per shipment and you receive monthly deliveries, that is $240 per year on top of the medication cost.

Dose Escalation Price Increases

This is the hidden cost most people overlook. Tirzepatide treatment typically starts at 2.5 mg and escalates to higher doses over several months. At BiltRx, the $129 flat rate applies regardless of dose. At Arc-1, the price jumps from $199.99 at 2.5 mg to $249.99 at 5 mg and $399.99 at 7.5 mg. A patient who starts at 2.5 mg and moves to 7.5 mg over 6 months will see their Arc-1 monthly cost double. The annual figure calculated at the starting dose does not reflect what most patients actually pay across a full treatment course.

Brand-Name Tirzepatide Cost for Reference

Brand-name tirzepatide is sold under two trade names. Mounjaro is approved for type 2 diabetes. Zepbound is approved for chronic weight management. Both contain the same active ingredient at the same doses. The price is the same.

Insurance coverage for brand-name tirzepatide is inconsistent. Many commercial plans cover Mounjaro for type 2 diabetes but exclude Zepbound for weight loss. Medicare Part D does not cover anti-obesity medications. Patients without coverage face the full $1,499 monthly cost. This is the primary reason compounded alternatives have become so popular despite the lack of FDA approval.